Dragonfly Therapeutics Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Dragonfly Therapeutics's estimated annual revenue is currently $13.2M per year.
- Dragonfly Therapeutics received $Undisclosed in venture funding in May 2017.
- Dragonfly Therapeutics's estimated revenue per employee is $155,000
- Dragonfly Therapeutics has 85 Employees.
- Dragonfly Therapeutics grew their employee count by 49% last year.
- Dragonfly Therapeutics currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Pricing|
|Cell Signaling ...||$89.4M||577||N/A||N/A||N/A|
What Is Dragonfly Therapeutics?
Dragonfly Therapeutics is a discovery-stage company developing drugs to stimulate immune responses against cancer. We are developing novel first-in-class therapeutics targeted at natural killer cells and other cells of the innate immune system. These therapies are designed to counterbalance immune suppressive factors present in the tumor microenvironment and mobilize anti-cancer immune responses. Our molecules are expected to be potent as single agents as well as in treatment combinations with existing cancer immunotherapies. Our scientific founders are major figures in cancer biology and immunology and have launched Dragonfly to harness the power of the immune system to provide breakthrough cancer treatments for patients. For more information, email email@example.com:N/A
Number of Employees
Employee Growth %
|Steve O'Neil||Principal Scientist||Email Available|
|Michael Shifrin||Associate Director||Email Available|
|Stacey Drabic||Director of Biology||Email Available|
|Hemanta Baruah||Associate Director Of Protein Engineering||Email Available|
|Patrick Kirby||Senior Director, Toxicology||Email Available|
|Sean Juo||Director, Protein Engineering||Email Available|
|Sean Rossi||Associate Director||Email Available|
|Anita Scheuber||Vice President Of Clinical Research|
|Lynn Markowitz||Associate Director, Bioanalytical Sciences And Preclinical Development||Email Available|
|Marianna Rowlands||Director of Biology, Immuno-Oncology|
Dragonfly Therapeutics News
4, 2019 /PRNewswire/ -- Skyhawk Therapeutics, Inc. ("Skyhawk"), today ... said Bill Haney, co-founder and CEO of Dragonfly Therapeutics.
Dr. Alan Korman, renowned for his work leading to the development the first approved checkpoint inhibitor cancer therapies, joins Dragonfly's ...
More than a year after insect-inspired biotech Dragonfly Therapeutics penned a blood cancer pact with big biotech Celgene, it's back at the ...
Dragonfly Therapeutics Funding
Dragonfly Therapeutics Executive Hires
|2017-05-17||Ann Cheung||Head Of Biology||Article|
|2018-01-30||Jean Marie Cuillerot||Chief Medical Officer||Article|